Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.

Pandolfi A, Barreyro L, Steidl U.

Stem Cells Transl Med. 2013 Feb;2(2):143-50. doi: 10.5966/sctm.2012-0109. Epub 2013 Jan 24. Review.

2.

Identifying leukemia stem cells--is it feasible and does it matter?

Lutz C, Hoang VT, Buss E, Ho AD.

Cancer Lett. 2013 Sep 10;338(1):10-4. doi: 10.1016/j.canlet.2012.07.014. Epub 2012 Jul 20. Review.

PMID:
22820159
3.

The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression.

Wong P, Iwasaki M, Somervaille TC, Ficara F, Carico C, Arnold C, Chen CZ, Cleary ML.

Cancer Res. 2010 May 1;70(9):3833-42. doi: 10.1158/0008-5472.CAN-09-3268. Epub 2010 Apr 20.

4.

Preferential induction of apoptosis for primary human leukemic stem cells.

Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, Jordan CT.

Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16220-5. Epub 2002 Nov 25.

5.

Leukemia stem cells.

Buss EC, Ho AD.

Int J Cancer. 2011 Nov 15;129(10):2328-36. doi: 10.1002/ijc.26318. Epub 2011 Sep 14. Review.

6.

Therapeutic implications of leukemia stem cell development.

Stubbs MC, Armstrong SA.

Clin Cancer Res. 2007 Jun 15;13(12):3439-42. Review.

7.

Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.

Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA.

JAMA. 2010 Dec 22;304(24):2706-15. doi: 10.1001/jama.2010.1862.

8.

Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.

Schuurhuis GJ, Meel MH, Wouters F, Min LA, Terwijn M, de Jonge NA, Kelder A, Snel AN, Zweegman S, Ossenkoppele GJ, Smit L.

PLoS One. 2013 Nov 11;8(11):e78897. doi: 10.1371/journal.pone.0078897. eCollection 2013.

9.

Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance.

Hoang VT, Zepeda-Moreno A, Ho AD.

Biotechnol J. 2012 Jun;7(6):779-88. doi: 10.1002/biot.201100350. Epub 2012 May 16. Review.

PMID:
22588704
10.

Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia.

Zhou J, Chng WJ.

World J Stem Cells. 2014 Sep 26;6(4):473-84. doi: 10.4252/wjsc.v6.i4.473. Review.

11.

Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.

Chan SM, Majeti R.

Int J Hematol. 2013 Dec;98(6):648-57. doi: 10.1007/s12185-013-1407-8. Epub 2013 Aug 15. Review.

PMID:
23949914
12.

Chronic myeloid leukemia stem cell biology.

Crews LA, Jamieson CH.

Curr Hematol Malig Rep. 2012 Jun;7(2):125-32. doi: 10.1007/s11899-012-0121-6.

13.

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA.

Nature. 2006 Aug 17;442(7104):818-22. Epub 2006 Jul 16.

PMID:
16862118
14.

Leukemia stem cells.

Lane SW, Gilliland DG.

Semin Cancer Biol. 2010 Apr;20(2):71-6. doi: 10.1016/j.semcancer.2009.12.001. Epub 2009 Dec 22. Review.

PMID:
20026405
15.

Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.

Moore MA, Dorn DC, Schuringa JJ, Chung KY, Morrone G.

Exp Hematol. 2007 Apr;35(4 Suppl 1):105-16.

PMID:
17379095
16.

Genetic and epigenetic alterations that drive leukemic stem cell self-renewal.

van den Boom V, Horton SJ, Schuringa JJ.

J Stem Cells. 2012;7(3):155-79. doi: jsc.2012.7.3.155. Review.

PMID:
23619382
17.

GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis.

Dietrich PA, Yang C, Leung HH, Lynch JR, Gonzales E, Liu B, Haber M, Norris MD, Wang J, Wang JY.

Blood. 2014 Nov 20;124(22):3284-94. doi: 10.1182/blood-2013-10-532523. Epub 2014 Oct 7.

18.

Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.

Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML.

Genes Dev. 2007 Nov 1;21(21):2762-74. Epub 2007 Oct 17. Erratum in: Genes Dev. 2007 Nov 15;21(22):3017. So, Chai Wai Eric [corrected to So, Chi Wai Eric].

19.

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.

Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M, Aztberger A, Schuh A, Grimwade D, Ivey A, Virgo P, Hills R, McSkeane T, Arrazi J, Knapper S, Brookes C, Davies B, Price A, Wall K, Griffiths M, Cavenagh J, Majeti R, Weissman I, Burnett A, Vyas P.

Leukemia. 2013 Apr;27(5):1028-36. doi: 10.1038/leu.2012.312. Epub 2012 Nov 6.

PMID:
23223186
20.

Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.

Kornblau SM, Qutub A, Yao H, York H, Qiu YH, Graber D, Ravandi F, Cortes J, Andreeff M, Zhang N, Coombes KR.

PLoS One. 2013 Oct 24;8(10):e78453. doi: 10.1371/journal.pone.0078453. eCollection 2013.

Items per page

Supplemental Content

Write to the Help Desk